Master bibliography — lung squamous cell carcinoma

Last curated: 2026-08-30. One line per paper, using metadata re-fetched from PubMed E-utilities in the audit session. 326 unique PubMed records are represented. Each entry maps its canonical citing wiki pages; separately tagged literature-layer uses are included where relevant. Clinical-trial registry records are catalogued separately in wiki/clinical-trials-landscape.md, and guideline web documents in guidelines/REGISTRY.md.

A PMID confirms an indexed record, not that every claim made from it is causal or generalizable. Page-level text preserves design, population, effect size, and limitations.

Foundations and overview

• Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9. PMID 18506026 — tags: [chemotherapy-and-histology-constraints, early-stage-and-perioperative-therapy, guidelines, overview] — cited by: chemotherapy-and-histology-constraints.md, early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42. PMID 20818875 — tags: [guidelines, overview, patient-experience-and-advocacy, systemic-therapy] — cited by: guidelines.md, overview.md, patient-experience-and-advocacy.md, systemic-therapy.md
• Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. PMID 21160078 — tags: [failed-and-frontier-targets, molecular-landscape, overview] — cited by: failed-and-frontier-targets.md, molecular-landscape.md, overview.md
• National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. PMID 21714641 — tags: [epidemiology-and-smoking, overview, screening-and-early-detection] — cited by: epidemiology-and-smoking.md, overview.md, screening-and-early-detection.md
• Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):64-70. PMID 21119545 — tags: [chemotherapy-and-histology-constraints, histology-and-diagnosis, overview] — cited by: chemotherapy-and-histology-constraints.md, histology-and-diagnosis.md, overview.md
• Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85. PMID 21252716 — tags: [overview] — cited by: overview.md
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. PMID 22960745 — tags: [biomarkers, failed-and-frontier-targets, guidelines, molecular-landscape, overview] — cited by: biomarkers.md, failed-and-frontier-targets.md, guidelines.md, molecular-landscape.md, overview.md
• Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210-9. PMID 22052329 — tags: [epidemiology-and-smoking, overview, screening-and-early-detection] — cited by: epidemiology-and-smoking.md, overview.md, screening-and-early-detection.md
• Carter-Harris L, Hermann CP, Schreiber J, Weaver MT, Rawl SM. Lung cancer stigma predicts timing of medical help-seeking behavior. Oncol Nurs Forum. 2014;41(3):E203-10. PMID 24769603 — tags: [overview, patient-experience-and-advocacy] — cited by: overview.md, patient-experience-and-advocacy.md
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. PMID 26028407 — tags: [biomarkers, chemotherapy-and-histology-constraints, clinical-trials-landscape, immunotherapy, overview, systemic-therapy] — cited by: biomarkers.md, chemotherapy-and-histology-constraints.md, clinical-trials-landscape.md, immunotherapy.md, overview.md, systemic-therapy.md
• Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514-24. PMID 25680375 — tags: [clinical-trials-landscape, overview] — cited by: clinical-trials-landscape.md, overview.md
• Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015;10(3):e0121323. PMID 25822850 — tags: [epidemiology-and-smoking, overview] — cited by: epidemiology-and-smoking.md, overview.md
• Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7(12):1394-1403. PMID 28899864 — tags: [biomarkers, overview] — cited by: biomarkers.md, overview.md
• Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2):208-222. PMID 27913228 — tags: [biomarkers, guidelines, overview] — cited by: biomarkers.md, guidelines.md, overview.md
• Olsson AC, Vermeulen R, Schüz J, Kromhout H, Pesch B, Peters S, et al. Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. Epidemiology. 2017;28(2):288-299. PMID 28141674 — tags: [epidemiology-and-smoking, overview] — cited by: epidemiology-and-smoking.md, overview.md
• Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129-159. PMID 29398453 — tags: [guidelines, histology-and-diagnosis, overview] — cited by: guidelines.md, histology-and-diagnosis.md, overview.md
• Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. PMID 30280635 — tags: [biomarkers, chemotherapy-and-histology-constraints, clinical-trials-landscape, guidelines, immunotherapy, overview, systemic-therapy] — cited by: biomarkers.md, chemotherapy-and-histology-constraints.md, clinical-trials-landscape.md, guidelines.md, immunotherapy.md, overview.md, systemic-therapy.md
• Ostroff JS, Riley KE, Shen MJ, Atkinson TM, Williamson TJ, Hamann HA. Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. Psychooncology. 2019;28(5):1011-1017. PMID 30779396 — tags: [overview, patient-experience-and-advocacy] — cited by: overview.md, patient-experience-and-advocacy.md
• Li C, Wang C, Yu J, Fan Y, Liu D, Zhou W, et al. Residential Radon and Histological Types of Lung Cancer: A Meta-Analysis of Case‒Control Studies. Int J Environ Res Public Health. 2020;17(4). PMID 32102460 — tags: [epidemiology-and-smoking, overview] — cited by: epidemiology-and-smoking.md, overview.md
• de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-513. PMID 31995683 — tags: [epidemiology-and-smoking, overview, screening-and-early-detection] — cited by: epidemiology-and-smoking.md, overview.md, screening-and-early-detection.md
• Caini S, Del Riccio M, Vettori V, Scotti V, Martinoli C, Raimondi S, et al. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2022;17(5):623-636. PMID 34995798 — tags: [early-stage-and-perioperative-therapy, epidemiology-and-smoking, overview] — cited by: early-stage-and-perioperative-therapy.md, epidemiology-and-smoking.md, overview.md
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. PMID 35403841 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines, overview] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617. PMID 35461558 — tags: [early-stage-and-perioperative-therapy, guidelines, overview] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. PMID 35108059 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines, immunotherapy, overview] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md, immunotherapy.md, overview.md
• Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553-562. PMID 37055640 — tags: [biomarkers, clinical-trials-landscape, overview] — cited by: biomarkers.md, clinical-trials-landscape.md, overview.md
• Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023;388(6):489-498. PMID 36780674 — tags: [early-stage-and-perioperative-therapy, guidelines, overview] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672-1684. PMID 37870974 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines, overview] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. PMID 36735893 — tags: [clinical-trials-landscape, immunotherapy, overview, systemic-therapy] — cited by: clinical-trials-landscape.md, immunotherapy.md, overview.md, systemic-therapy.md
• Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024;390(19):1756-1769. PMID 38749033 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines, overview] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md, overview.md
• Fong KM, Rosenthal A, Giroux DJ, Nishimura KK, Erasmus J, Lievens Y, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):786-802. PMID 38320664 — tags: [overview, staging] — cited by: overview.md, staging.md
• Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(7):1007-1027. PMID 38447919 — tags: [early-stage-and-perioperative-therapy, guidelines, overview, staging] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md, overview.md, staging.md
• Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240-1252. PMID 39288781 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, overview] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, overview.md
• Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43(3):260-272. PMID 39250535 — tags: [clinical-trials-landscape, overview, systemic-therapy] — cited by: clinical-trials-landscape.md, overview.md, systemic-therapy.md
• Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348-363. PMID 39914442 — tags: [epidemiology-and-smoking, overview] — cited by: epidemiology-and-smoking.md, overview.md
• Mahmood K, Frazer-Green L, Gonzalez AV, Shofer SL, Argento AC, Welsby I, et al. Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025;167(1):283-295. PMID 39029785 — tags: [central-airway-biology-and-presentation, overview, red-flags-and-safety-concerns] — cited by: central-airway-biology-and-presentation.md, overview.md, red-flags-and-safety-concerns.md

Epidemiology, exposure, and screening

• Morabia A, Wynder EL. Cigarette smoking and lung cancer cell types. Cancer. 1991;68(9):2074-8. PMID 1655236 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest. 1997;112(6):1474-9. PMID 9404741 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120(5):1577-83. PMID 11713137 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31(2-3):139-48. PMID 11165392 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, et al. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer. 2005;49(2):187-91. PMID 16022912 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005;237(1):342-7. PMID 16183941 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Taeger D, Fritsch A, Wiethege T, Johnen G, Eisenmenger A, Wesch H, et al. Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners. Cancer. 2006;106(4):881-9. PMID 16411224 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Liaw YP, Ting TF, Ho KK, Yang CF. Cell type specificity of lung cancer associated with air pollution. Sci Total Environ. 2008;395(1):23-7. PMID 18346778 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94. PMID 18452692 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Siew SS, Kauppinen T, Kyyrönen P, Heikkilä P, Pukkala E. Exposure to iron and welding fumes and the risk of lung cancer. Scand J Work Environ Health. 2008;34(6):444-50. PMID 19137206 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Lam B, Lam SY, Wong MP, Ooi CG, Fong DY, Lam DC, et al. Sputum cytology examination followed by autofluorescence bronchoscopy: a practical way of identifying early stage lung cancer in central airway. Lung Cancer. 2009;64(3):289-94. PMID 19010567 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569. PMID 20093278 — tags: [early-stage-and-perioperative-therapy, epidemiology-and-smoking] — cited by: early-stage-and-perioperative-therapy.md, epidemiology-and-smoking.md
• Salmerón D, Chirlaque MD, Isabel Izarzugaza M, Sánchez MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301-8. PMID 22749756 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Cheng I, Le GM, Noone AM, Gali K, Patel M, Haile RW, et al. Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2250-65. PMID 25368400 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR Lung-RADS in a clinical CT lung screening program. J Am Coll Radiol. 2015;12(3):273-6. PMID 25176499 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• van Boerdonk RA, Smesseim I, Heideman DA, Coupé VM, Tio D, Grünberg K, et al. Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. Am J Respir Crit Care Med. 2015;192(12):1483-9. PMID 26275031 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653-71. PMID 27364315 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Eckel SP, Cockburn M, Shu YH, Deng H, Lurmann FW, Liu L, et al. Air pollution affects lung cancer survival. Thorax. 2016;71(10):891-8. PMID 27491839 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Leng S, Thomas CL, Snider AM, Picchi MA, Chen W, Willis DG, et al. Radon Exposure, IL-6 Promoter Variants, and Lung Squamous Cell Carcinoma in Former Uranium Miners. Environ Health Perspect. 2016;124(4):445-51. PMID 26372664 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Katki HA, Kovalchik SA, Petito LC, Cheung LC, Jacobs E, Jemal A, et al. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening. Ann Intern Med. 2018;169(1):10-19. PMID 29800127 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun. 2019;10(1):1856. PMID 31015447 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019;14(10):1732-1742. PMID 31260833 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Lebrett MB, Balata H, Evison M, Colligan D, Duerden R, Elton P, et al. Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme. Thorax. 2020;75(8):661-668. PMID 32631933 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J, Borràs JM, et al. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Sci Rep. 2021;11(1):23274. PMID 34857781 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971-987. PMID 33687468 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Pinsky PF, Lau YK, Doubeni CA. Potential Disparities by Sex and Race or Ethnicity in Lung Cancer Screening Eligibility Rates. Chest. 2021;160(1):341-350. PMID 33545164 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Reese TJ, Schlechter CR, Potter LN, Kawamoto K, Del Fiol G, Lam CY, et al. Evaluation of Revised US Preventive Services Task Force Lung Cancer Screening Guideline Among Women and Racial/Ethnic Minority Populations. JAMA Netw Open. 2021;4(1):e2033769. PMID 33433600 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022;8(8):CD013829. PMID 35921047 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Guisier F, Deslee G, Birembaut P, Escarguel B, Chapel F, Bota S, et al. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial. Eur Respir J. 2022;60(3). PMID 35236723 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Lancaster HL, Heuvelmans MA, Oudkerk M. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research. J Intern Med. 2022;292(1):68-80. PMID 35253286 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Taylor KL, Williams RM, Li T, Luta G, Smith L, Davis KM, et al. A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting. J Natl Cancer Inst. 2022;114(10):1410-1419. PMID 35818122 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Zou K, Sun P, Huang H, Zhuo H, Qie R, Xie Y, et al. Etiology of lung cancer: Evidence from epidemiologic studies. J Natl Cancer Cent. 2022;2(4):216-225. PMID 39036545 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet. 2023;401(10374):390-408. PMID 36563698 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Liu HI, Chiang CJ, Su SY, Jhuang JR, Tsai DR, Yang YW, et al. Incidence trends and spatial distributions of lung adenocarcinoma and squamous cell carcinoma in Taiwan. Sci Rep. 2023;13(1):1655. PMID 36717588 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Manyak A, Seaburg L, Bohreer K, Kirtland SH, Hubka M, Gerbino AJ. Invasive Procedures Associated With Lung Cancer Screening in Clinical Practice. Chest. 2023;164(2):544-555. PMID 36781101 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Smeltzer MP, Liao W, Faris NR, Fehnel C, Goss J, Shepherd CJ, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158-168. PMID 36208717 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206-1218. PMID 37837979 — tags: [epidemiology-and-smoking] — cited by: epidemiology-and-smoking.md
• Potter AL, Xu NN, Senthil P, Srinivasan D, Lee H, Gazelle GS, et al. Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility. J Clin Oncol. 2024;42(17):2026-2037. PMID 38537159 — tags: [screening-and-early-detection] — cited by: screening-and-early-detection.md
• Zhou J, Yu B, Guo P, Wang S. The insufficiency of CT examination in early detection of central lung squamous cell carcinoma and squamous epithelial precancerous lesions. BMC Cancer. 2024;24(1):299. PMID 38443800 — tags: [central-airway-biology-and-presentation, screening-and-early-detection] — cited by: central-airway-biology-and-presentation.md, screening-and-early-detection.md
• Gendarme S, Irajizad E, Long JP, Fahrmann JF, Dennison JB, Ghasemi SM, et al. Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. J Thorac Oncol. 2025;20(5):565-576. PMID 39798695 — tags: [epidemiology-and-smoking, screening-and-early-detection] — cited by: epidemiology-and-smoking.md, screening-and-early-detection.md

Pathogenesis, presentation, pathology, and staging

• Tomashefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med. 1990;114(5):468-74. PMID 2334253 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995;55(6):1365-72. PMID 7882337 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res. 1995;55(22):5133-9. PMID 7585560 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Kurie JM, Lee JS, Morice RC, Walsh GL, Khuri FR, Broxson A, et al. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst. 1998;90(13):991-5. PMID 9665147 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003;27(7):978-84. PMID 12826890 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27(2):150-8. PMID 12548160 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 2004;78(1):222-7. PMID 15223433 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest. 2006;130(6):1803-7. PMID 17167000 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Rolston KVI, Nesher L. Post-Obstructive Pneumonia in Patients with Cancer: A Review. Infect Dis Ther. 2018;7(1):29-38. PMID 29392577 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50. PMID 17167137 — tags: [chemotherapy-and-histology-constraints, histology-and-diagnosis, systemic-therapy] — cited by: chemotherapy-and-histology-constraints.md, histology-and-diagnosis.md, systemic-therapy.md
• Loewen G, Natarajan N, Tan D, Nava E, Klippenstein D, Mahoney M, et al. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax. 2007;62(4):335-40. PMID 17101735 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, et al. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev. 2008;17(1):158-62. PMID 18199720 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg. 2008;33(3):466-9. PMID 18249130 — tags: [staging] — cited by: staging.md
• Banerjee AK. Preinvasive lesions of the bronchus. J Thorac Oncol. 2009;4(4):545-51. PMID 19279508 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J. 2009;33(2):352-9. PMID 19010987 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 2010;29(1):5-14. PMID 20112052 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):442-7. PMID 20195168 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 2010;182(1):83-91. PMID 20299530 — tags: [central-airway-biology-and-presentation, molecular-landscape] — cited by: central-airway-biology-and-presentation.md, molecular-landscape.md
• Alaa M, Shibuya K, Fujiwara T, Wada H, Hoshino H, Yoshida S, et al. Risk of lung cancer in patients with preinvasive bronchial lesions followed by autofluorescence bronchoscopy and chest computed tomography. Lung Cancer. 2011;72(3):303-8. PMID 21040997 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Paech DC, Weston AR, Pavlakis N, Gill A, Rajan N, Barraclough H, et al. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):55-63. PMID 21107286 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Gruver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136(11):1339-46. PMID 23106579 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med. 2012;185(12):1316-22. PMID 22505743 — tags: [histology-and-diagnosis, staging] — cited by: histology-and-diagnosis.md, staging.md
• Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med. 2013;137(1):32-40. PMID 22583114 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992-1001. PMID 23401443 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Ao MH, Zhang H, Sakowski L, Sharma R, Illei PB, Gabrielson E, et al. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol. 2014;45(5):926-34. PMID 24746197 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787-98. PMID 24578407 — tags: [staging] — cited by: staging.md
• Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax. 2014;69(6):548-57. PMID 24550057 — tags: [central-airway-biology-and-presentation, molecular-landscape, staging] — cited by: central-airway-biology-and-presentation.md, molecular-landscape.md, staging.md
• Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab. 2015;100(5):2024-9. PMID 25719931 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Nakao M, Hoshi R, Ishikawa Y, Matsuura Y, Uehara H, Mun M, et al. Prognosis of non-small-cell lung cancer patients with positive pleural lavage cytology. Interact Cardiovasc Thorac Surg. 2015;20(6):777-82. PMID 25762707 — tags: [staging] — cited by: staging.md
• Razazi K, Parrot A, Khalil A, Djibre M, Gounant V, Assouad J, et al. Severe haemoptysis in patients with nonsmall cell lung carcinoma. Eur Respir J. 2015;45(3):756-64. PMID 25359349 — tags: [central-airway-biology-and-presentation, chemotherapy-and-histology-constraints] — cited by: central-airway-biology-and-presentation.md, chemotherapy-and-histology-constraints.md
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260. PMID 26291008 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Tsutani Y, Miyata Y, Mimura T, Kushitani K, Takeshima Y, Yoshimura M, et al. Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2015;63(3):153-8. PMID 25248914 — tags: [staging] — cited by: staging.md
• Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, et al. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type? Oncotarget. 2015;6(27):23905-16. PMID 26068980 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47(6):545-59. PMID 26030890 — tags: [staging] — cited by: staging.md
• Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. PMID 26762738 — tags: [staging] — cited by: staging.md
• Klebe S, Swalling A, Jonavicius L, Henderson DW. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. J Clin Pathol. 2016;69(2):136-41. PMID 26281863 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Krimsky W, Muganlinskaya N, Sarkar S, Vulchi M, Patel P, Rao S, et al. The changing anatomic position of squamous cell carcinoma of the lung - a new conundrum. J Community Hosp Intern Med Perspect. 2016;6(6):33299. PMID 27987285 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Tran L, Mattsson JS, Nodin B, Jönsson P, Planck M, Jirström K, et al. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2016;24(9):648-659. PMID 26447895 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Zakowski MF, Rekhtman N, Auger M, Booth CN, Crothers B, Ghofrani M, et al. Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens. Arch Pathol Lab Med. 2016;140(10):1116-20. PMID 27552093 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Walia R, Jain D, Madan K, Sharma MC, Mathur SR, Mohan A, et al. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category. Indian J Med Res. 2017;146(1):42-48. PMID 29168459 — tags: [chemotherapy-and-histology-constraints, histology-and-diagnosis] — cited by: chemotherapy-and-histology-constraints.md, histology-and-diagnosis.md
• Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel). 2018;10(3). PMID 29538329 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Latimer KM. Lung Cancer: Clinical Presentation and Diagnosis. FP Essent. 2018;464:23-26. PMID 29313654 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Li C, Lu H. Adenosquamous carcinoma of the lung. Onco Targets Ther. 2018;11:4829-4835. PMID 30147334 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, et al. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018;78(17):4971-4983. PMID 29997230 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14(12):2109-2119. PMID 31398540 — tags: [staging] — cited by: staging.md
• Kriegsmann K, Cremer M, Zgorzelski C, Harms A, Muley T, Winter H, et al. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. Pathology. 2019;51(3):240-245. PMID 30798982 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Lin MW, Huang YL, Yang CY, Kuo SW, Wu CT, Chang YL. The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2019;26(1):217-229. PMID 30456676 — tags: [central-airway-biology-and-presentation, staging] — cited by: central-airway-biology-and-presentation.md, staging.md
• McAleese J, Taylor A, Walls GM, Hanna GG. Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology. Clin Oncol (R Coll Radiol). 2019;31(10):711-719. PMID 31351746 — tags: [staging] — cited by: staging.md
• Vigliar E, Malapelle U, Bono F, Fusco N, Cortinovis D, Valtorta E, et al. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. Biomed Res Int. 2019;2019:6832909. PMID 31111063 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Beyaz F, Verhoeven RLJ, Schuurbiers OCJ, Verhagen AFTM, van der Heijden EHFM. Occult lymph node metastases in clinical N0/N1 NSCLC; A single center in-depth analysis. Lung Cancer. 2020;150:186-194. PMID 33189983 — tags: [staging] — cited by: staging.md
• Ito H, Matsuo Y, Ohtsu S, Nishimura T, Terada Y, Sakamoto T, et al. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. Int J Clin Oncol. 2020;25(2):274-281. PMID 31667664 — tags: [staging] — cited by: staging.md
• Naso JR, Churg A. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Hum Pathol. 2020;100:10-14. PMID 32333920 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Schulte JJ, Steinmetz J, Furtado LV, Husain AN, Lingen MW, Cipriani NA. Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful? Head Neck Pathol. 2020;14(4):966-973. PMID 32350806 — tags: [histology-and-diagnosis, staging] — cited by: histology-and-diagnosis.md, staging.md
• Chen H, Katakura S, Horita N, Namkoong H, Kato I, Hara Y, et al. Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy. Ther Adv Med Oncol. 2022;14:17588359211065152. PMID 35126682 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022;40(12):1356-1384. PMID 34936470 — tags: [early-stage-and-perioperative-therapy, guidelines, staging] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md, staging.md
• Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362-387. PMID 34808341 — tags: [histology-and-diagnosis] — cited by: histology-and-diagnosis.md
• Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V, et al. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2023;18(5):564-575. PMID 36773775 — tags: [staging] — cited by: staging.md
• Chaddha U, Agrawal A, Kurman J, Ortiz-Comino R, Dutau H, Freitag L, et al. World Association for Bronchology and Interventional Pulmonology (WABIP) guidelines on airway stenting for malignant central airway obstruction. Respirology. 2024;29(7):563-573. PMID 38812262 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Detterbeck FC, Ostrowski M, Hoffmann H, Rami-Porta R, Osarogiagbon RU, Donnington J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2024;19(7):1052-1072. PMID 38569931 — tags: [staging] — cited by: staging.md
• Huang J, Osarogiagbon RU, Giroux DJ, Nishimura KK, Bille A, Cardillo G, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):766-785. PMID 37866624 — tags: [staging] — cited by: staging.md
• Ivanick NM, Kunadharaju R, Bhura S, Mengiste H, Saeed M, Saradna A, et al. Epidemiology and Survival of Malignant Central Airway Obstruction in Lung Cancer Identified on Cross-Sectional Imaging. J Bronchology Interv Pulmonol. 2024;31(3). PMID 38881337 — tags: [central-airway-biology-and-presentation] — cited by: central-airway-biology-and-presentation.md
• Kim IH, Lee GD, Choi S, Kim HR, Kim YH, Kim DK, et al. Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19(8):1218-1227. PMID 38614456 — tags: [staging] — cited by: staging.md
• Son JW, Lee J, Jeon JH, Cho S, Jung W, Shih BC, et al. Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor. BMC Cancer. 2024;24(1):1460. PMID 39604857 — tags: [staging] — cited by: staging.md
• Travis WD, Eisele M, Nishimura KK, Aly RG, Bertoglio P, Chou TY, et al. The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC. J Thorac Oncol. 2024;19(7):1028-1051. PMID 38508515 — tags: [staging] — cited by: staging.md
• Van Schil PE, Asamura H, Nishimura KK, Rami-Porta R, Kim YT, Bertoglio P, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):749-765. PMID 38070600 — tags: [staging] — cited by: staging.md
• Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, et al. An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer. Lung Cancer. 2025;199:108061. PMID 39705827 — tags: [staging] — cited by: staging.md
• Kuhtić I, Mandić Paulić T, Kovačević L, Badovinac S, Jakopović M, Dobrenić M, et al. Clinical TNM Lung Cancer Staging: A Diagnostic Algorithm with a Pictorial Review. Diagnostics (Basel). 2025;15(7). PMID 40218258 — tags: [staging] — cited by: staging.md

Molecular landscape, biomarkers, and targets

• Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16(14):3743-53. PMID 20534738 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011;1(1):78-89. PMID 22328973 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. PMID 23980093 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, et al. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. 2014;13(2):475-82. PMID 24296828 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi T, Taira T, et al. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer. 2014;14:786. PMID 25348872 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer. 2015;87(1):1-7. PMID 25433983 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Stamatkin C, Ratermann KL, Overley CW, Black EP. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther. 2015;16(9):1341-52. PMID 26176612 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-74. PMID 26045340 — tags: [chemotherapy-and-histology-constraints, failed-and-frontier-targets] — cited by: chemotherapy-and-histology-constraints.md, failed-and-frontier-targets.md
• Weeden CE, Solomon B, Asselin-Labat ML. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov. 2015;1:15049. PMID 27551478 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer. 2016;122(19):3024-31. PMID 27315356 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016;27(8):1573-9. PMID 27207107 — tags: [chemotherapy-and-histology-constraints, failed-and-frontier-targets] — cited by: chemotherapy-and-histology-constraints.md, failed-and-frontier-targets.md
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. PMID 27718847 — tags: [biomarkers, immunotherapy, systemic-therapy] — cited by: biomarkers.md, immunotherapy.md, systemic-therapy.md
• Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. PMID 28445469 — tags: [biomarkers, molecular-landscape] — cited by: biomarkers.md, molecular-landscape.md
• Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, et al. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Carcinogenesis. 2017;38(11):1063-1072. PMID 28968756 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. J Thorac Oncol. 2017;12(6):943-953. PMID 28341226 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov. 2017;7(1):86-101. PMID 27663899 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Kasiri S, Shao C, Chen B, Wilson AN, Yenerall P, Timmons BC, et al. GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. Cancer Res. 2017;77(16):4448-4459. PMID 28652248 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Nakamura S, Hayashi K, Imaoka Y, Kitamura Y, Akazawa Y, Tabata K, et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS One. 2017;12(10):e0186192. PMID 29049375 — tags: [biomarkers] — cited by: biomarkers.md
• Weeden CE, Holik AZ, Young RJ, Ma SB, Garnier JM, Fox SB, et al. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2017;16(8):1610-1622. PMID 28611104 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018;23(1):194-212.e6. PMID 29617660 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Cancer Res. 2018;24(13):3087-3096. PMID 29615460 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018;4(9):1189-1197. PMID 29902295 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-2104. PMID 29658845 — tags: [biomarkers] — cited by: biomarkers.md
• Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13(9):1302-1311. PMID 29800747 — tags: [biomarkers] — cited by: biomarkers.md
• Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1847-1852. PMID 31195180 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1853-1859. PMID 31302234 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-2031. PMID 31562796 — tags: [biomarkers, systemic-therapy] — cited by: biomarkers.md, systemic-therapy.md
• Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, et al. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019;14(10):1839-1846. PMID 31158500 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, et al. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. J Natl Cancer Inst. 2019;111(6):575-583. PMID 30496436 — tags: [biomarkers] — cited by: biomarkers.md
• Saito Y, Horiuchi S, Morooka H, Ibi T, Takahashi N, Ikeya T, et al. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. J Thorac Dis. 2019;11(12):4982-4991. PMID 32030214 — tags: [biomarkers] — cited by: biomarkers.md
• Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, et al. Proteogenomic landscape of squamous cell lung cancer. Nat Commun. 2019;10(1):3578. PMID 31395880 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Wu Z, Yang Z, Li CS, Zhao W, Liang ZX, Dai Y, et al. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Cancer Med. 2019;8(3):910-919. PMID 30767431 — tags: [biomarkers] — cited by: biomarkers.md
• Xie X, Liu J, Yang H, Chen H, Zhou S, Lin H, et al. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. Cancer Invest. 2019;37(6):265-274. PMID 31304800 — tags: [biomarkers] — cited by: biomarkers.md
• Ohara S, Suda K, Sakai K, Nishino M, Chiba M, Shimoji M, et al. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. Transl Lung Cancer Res. 2020;9(5):1915-1923. PMID 33209612 — tags: [biomarkers] — cited by: biomarkers.md
• Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21(12):1589-1601. PMID 33125909 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, et al. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2020;140:35-41. PMID 31855703 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Bensen R, Brognard J. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases. Int J Mol Sci. 2021;22(6). PMID 33799513 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, et al. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(9):1368-1377. PMID 34264316 — tags: [failed-and-frontier-targets, immunotherapy] — cited by: failed-and-frontier-targets.md, immunotherapy.md
• Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021;37:100940. PMID 34195574 — tags: [chemotherapy-and-histology-constraints, failed-and-frontier-targets] — cited by: chemotherapy-and-histology-constraints.md, failed-and-frontier-targets.md
• Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, et al. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021;9(8). PMID 34429332 — tags: [failed-and-frontier-targets, immunotherapy] — cited by: failed-and-frontier-targets.md, immunotherapy.md
• Li Y, Li M, Zhang Y, Zhou J, Jiang L, Yang C, et al. Age-stratified and gender-specific reference intervals of six tumor markers panel of lung cancer: A geographic-based multicenter study in China. J Clin Lab Anal. 2021;35(6):e23816. PMID 33982344 — tags: [biomarkers] — cited by: biomarkers.md
• Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12(1):6770. PMID 34799585 — tags: [biomarkers] — cited by: biomarkers.md
• Shen X, Wang Y, Jin Y, Zheng Q, Shen L, Chen Y, et al. PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis. J Thorac Dis. 2021;13(7):4360-4370. PMID 34422362 — tags: [biomarkers] — cited by: biomarkers.md
• Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clin Cancer Res. 2021;27(6):1631-1640. PMID 33355200 — tags: [biomarkers] — cited by: biomarkers.md
• Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, et al. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Med. 2022;14(1):39. PMID 35428358 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, et al. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022;21(9):1381-1392. PMID 35732569 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Platini H, Ferdinand E, Kohar K, Prayogo SA, Amirah S, Komariah M, et al. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2022;58(8). PMID 36013536 — tags: [biomarkers] — cited by: biomarkers.md
• Thompson JC, Aggarwal C, Wong J, Nimgaonkar V, Hwang WT, Andronov M, et al. Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study. JTO Clin Res Rep. 2022;3(4):100301. PMID 35392653 — tags: [biomarkers] — cited by: biomarkers.md
• Wang C, Yu Q, Song T, Wang Z, Song L, Yang Y, et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022;7(1):289. PMID 36008393 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, et al. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Clin Cancer Res. 2022;28(15):3308-3317. PMID 34844976 — tags: [biomarkers] — cited by: biomarkers.md
• Zhang L, Zhang Y, Wang C, Yang Y, Ni Y, Wang Z, et al. Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer. Signal Transduct Target Ther. 2022;7(1):9. PMID 35027529 — tags: [molecular-landscape] — cited by: molecular-landscape.md
• Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. Front Oncol. 2022;12:791496. PMID 35924149 — tags: [biomarkers] — cited by: biomarkers.md
• Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, et al. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer. J Clin Invest. 2023;133(21). PMID 37606995 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Paik PK, Fan PD, Qeriqi B, Namakydoust A, Daly B, Ahn L, et al. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. J Thorac Oncol. 2023;18(4):516-526. PMID 36240971 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, et al. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Clin Cancer Res. 2023;29(8):1506-1514. PMID 36201167 — tags: [biomarkers] — cited by: biomarkers.md
• Hong TH, Hwang S, Dasgupta A, Abbosh C, Hung T, Bredno J, et al. Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC. J Thorac Oncol. 2024;19(11):1512-1524. PMID 38992468 — tags: [biomarkers] — cited by: biomarkers.md
• Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, et al. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). J Thorac Oncol. 2024;19(12):1618-1629. PMID 39111731 — tags: [failed-and-frontier-targets, molecular-landscape] — cited by: failed-and-frontier-targets.md, molecular-landscape.md
• Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20(37):2927-2936. PMID 39469838 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md
• Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025;393(8):741-752. PMID 40454642 — tags: [biomarkers, early-stage-and-perioperative-therapy] — cited by: biomarkers.md, early-stage-and-perioperative-therapy.md
• Planchard D, Cozic N, Mosele MF, Corcos N, Le Bescond L, Pradat Y, et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell. 2026;44(6):1147-1159.e6. PMID 41999747 — tags: [failed-and-frontier-targets] — cited by: failed-and-frontier-targets.md

Therapy

• Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res. 2007;13(15 Pt 2):s4613-6. PMID 17671151 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-51. PMID 18506025 — tags: [chemotherapy-and-histology-constraints, systemic-therapy] — cited by: chemotherapy-and-histology-constraints.md, systemic-therapy.md
• Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009;36(1):181-4. PMID 19477657 — tags: [early-stage-and-perioperative-therapy, guidelines] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md
• Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253-63. PMID 19221167 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(4):620-7. PMID 20038726 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Hardy D, Cormier JN, Xing Y, Liu CC, Xia R, Du XL. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(1):90-8. PMID 19884853 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079-88. PMID 21831418 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology. 2011;16(8):1210-20. PMID 21801275 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012;20(11):2985-98. PMID 22956190 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823-1829. PMID 23154554 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-62. PMID 22547591 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73. PMID 24933332 — tags: [chemotherapy-and-histology-constraints, systemic-therapy] — cited by: chemotherapy-and-histology-constraints.md, systemic-therapy.md
• Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, et al. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015;16(2):137-43. PMID 25450871 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897-907. PMID 26156651 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. PMID 26712084 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R, et al. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016;11(6):808-18. PMID 26980471 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929. PMID 28885881 — tags: [early-stage-and-perioperative-therapy, guidelines, immunotherapy] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md, immunotherapy.md
• Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, et al. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Rev Respir Med. 2017;11(6):469-479. PMID 28467720 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, et al. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 2017;112:126-133. PMID 29191585 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. PMID 27979383 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. PMID 30280658 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Baine MJ, Verma V, Schonewolf CA, Lin C, Simone CB 2nd. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer. Lung Cancer. 2018;118:20-26. PMID 29571997 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, et al. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 2018;13(2):194-204. PMID 29129758 — tags: [immunotherapy] — cited by: immunotherapy.md
• Abel S, Hasan S, White R, Schumacher L, Finley G, Colonias A, et al. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. Lung Cancer. 2019;128:127-133. PMID 30642444 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558-1565. PMID 31067138 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, et al. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019;14(1):25-36. PMID 30253973 — tags: [immunotherapy] — cited by: immunotherapy.md
• Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877. PMID 32914866 — tags: [immunotherapy] — cited by: immunotherapy.md
• Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160-172. PMID 32028209 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655-663. PMID 32251621 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020;38(14):1580-1590. PMID 32078391 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328-1339. PMID 32997907 — tags: [immunotherapy] — cited by: immunotherapy.md
• Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020;15(8):1351-1360. PMID 32302702 — tags: [immunotherapy] — cited by: immunotherapy.md
• Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(3):271-280. PMID 31751163 — tags: [patient-experience-and-advocacy, systemic-therapy] — cited by: patient-experience-and-advocacy.md, systemic-therapy.md
• Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021;39(7):723-733. PMID 33449799 — tags: [immunotherapy] — cited by: immunotherapy.md
• Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357. PMID 34555333 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md
• Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. PMID 33476593 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. PMID 34724392 — tags: [immunotherapy, red-flags-and-safety-concerns] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
• Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. PMID 33581821 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28(11):2374-2380. PMID 36008722 — tags: [immunotherapy] — cited by: immunotherapy.md
• Hsiao SH, Chen WT, Chung CL, Chou YT, Lin SE, Hong SY, et al. Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung. Cancer Med. 2022;11(10):2067-2078. PMID 35274494 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274-1286. PMID 36108662 — tags: [clinical-trials-landscape, early-stage-and-perioperative-therapy, guidelines] — cited by: clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md
• Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2022;17(2):289-308. PMID 34648948 — tags: [immunotherapy] — cited by: immunotherapy.md
• Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022;17(4):544-557. PMID 34923163 — tags: [immunotherapy] — cited by: immunotherapy.md
• Yang M, Lin C, Wang Y, Chen K, Zhang H, Li W. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. Genome Med. 2022;14(1):72. PMID 35799269 — tags: [immunotherapy] — cited by: immunotherapy.md
• Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, et al. Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. Cell Rep Med. 2023;4(12):101302. PMID 38052215 — tags: [immunotherapy] — cited by: immunotherapy.md
• Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023;41(6):1213-1227. PMID 36327426 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, et al. A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS). Clin Lung Cancer. 2023;24(4):371-375. PMID 36849264 — tags: [chemotherapy-and-histology-constraints] — cited by: chemotherapy-and-histology-constraints.md
• Salvicchi A, Tombelli S, Mugnaini G, Gonfiotti A. Lung Segmentectomy in NSCLC Surgery. Life (Basel). 2023;13(6). PMID 37374067 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491-503. PMID 37272513 — tags: [early-stage-and-perioperative-therapy, guidelines] — cited by: early-stage-and-perioperative-therapy.md, guidelines.md
• Chen W, Liu H, Li Y, Xue W, Fan S, Sun J, et al. First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials. Front Oncol. 2024;14:1365255. PMID 38725635 — tags: [systemic-therapy] — cited by: systemic-therapy.md
• Deng T, Song J, Tuo J, Wang Y, Li J, Ping Suen LK, et al. Incidence and risk factors of pulmonary complications after lung cancer surgery: A systematic review and meta-analysis. Heliyon. 2024;10(12):e32821. PMID 38975138 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, Park HS, et al. The Proposed Ninth Edition TNM Classification of Lung Cancer. Chest. 2024;166(4):882-895. PMID 38885896 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Gadgeel SM, Rodríguez-Abreu D, Halmos B, Garassino MC, Kurata T, Cheng Y, et al. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024;19(8):1228-1241. PMID 38642841 — tags: [immunotherapy] — cited by: immunotherapy.md
• Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024;211:114296. PMID 39270380 — tags: [immunotherapy] — cited by: immunotherapy.md
• Brat K, Sova M, Homolka P, Plutinsky M, Genzor S, Pokorna A, et al. Multimodal prehabilitation before lung resection surgery: a multicentre randomised controlled trial. Br J Anaesth. 2025;135(1):188-196. PMID 40374400 — tags: [early-stage-and-perioperative-therapy] — cited by: early-stage-and-perioperative-therapy.md
• Carbone DP, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. ESMO Open. 2025;10(6):105123. PMID 40446626 — tags: [immunotherapy] — cited by: immunotherapy.md
• Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025;20(7):941-954. PMID 40118215 — tags: [immunotherapy] — cited by: immunotherapy.md
• Zhao X, Liu B, William WN, Tsanov KM, Ho YJ, Barriga FM, et al. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction. J Thorac Oncol. 2025;20(9):1177-1236. PMID 39725169 — tags: [immunotherapy] — cited by: immunotherapy.md
• Bazhenova L, Ismaila N, Durm G, Freeman-Daily J, Horinouchi H, MacVicar GR, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. J Clin Oncol. 2026;44(18):e101-e112. PMID 42190141 — tags: [guidelines, systemic-therapy] — cited by: guidelines.md, systemic-therapy.md
• Liu H, Gu Z, Yu K, Zhao ZR, Yan W, Fang Y, et al. Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non-Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study. Clin Lung Cancer. 2026;27(4):160-169.e5. PMID 42055888 — tags: [open-questions] — cited by: OPEN-QUESTIONS.md

Guidelines, trials, safety, and lived experience

• Sholl LM, Awad M, Basu Roy U, Beasley MB, Cartun RW, Hwang DM, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Arch Pathol Lab Med. 2024;148(7):757-774. PMID 38625026 — tags: [guidelines, biomarkers] — cited by: literature/guidelines/REGISTRY.md

• Curran WJ Jr, Schiller JH, Wolkin AC, Comis RL, Scientific Leadership Council in Lung Cancer of the Coalition of Cancer Cooperative Groups. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer. 2008;9(4):222-6. PMID 18650170 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md

• Tod AM, Craven J, Allmark P. Diagnostic delay in lung cancer: a qualitative study. J Adv Nurs. 2008;61(3):336-43. PMID 18197868 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Taylor JW, Schiff D. Metastatic epidural spinal cord compression. Semin Neurol. 2010;30(3):245-53. PMID 20577931 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Du Rand IA, Barber PV, Goldring J, Lewis RA, Mandal S, Munavvar M, et al. Summary of the British Thoracic Society guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax. 2011;66(11):1014-5. PMID 22003155 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Jones LW. Physical activity and lung cancer survivorship. Recent Results Cancer Res. 2011;186:255-74. PMID 21113768 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Yang P, Cheville AL, Wampfler JA, Garces YI, Jatoi A, Clark MM, et al. Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol. 2012;7(1):64-70. PMID 22134070 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013;14(1):14-8. PMID 22591607 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Savage P, Sharkey R, Kua T, Schofield L, Richardson D, Panchmatia N, et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM. 2014;107(4):277-82. PMID 24336849 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Warnock C, Hodson S, Tod A, Mills R, Crowther L, Buchanan J, et al. Improving care of patients with metastatic spinal cord compression. Br J Nurs. 2014;23(4):S14-8. PMID 24619048 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chin Clin Oncol. 2015;4(3):36. PMID 26408303 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
• Stevens DC, Butty S, Johnson MS. Superior Vena Cava Rupture and Cardiac Tamponade Complicating the Endovascular Treatment of Malignant Superior Vena Cava Syndrome: A Case Report and Literature Review. Semin Intervent Radiol. 2015;32(4):439-44. PMID 26622107 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Cordovilla R, Bollo de Miguel E, Nuñez Ares A, Cosano Povedano FJ, Herráez Ortega I, Jiménez Merchán R. Diagnosis and Treatment of Hemoptysis. Arch Bronconeumol. 2016;52(7):368-77. PMID 26873518 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Li S, Fan J, Liu J, Zhou J, Ren Y, Shen C, et al. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients. Jpn J Clin Oncol. 2016;46(6):534-46. PMID 27052116 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016;22(24):6051-6060. PMID 27535979 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Shen MJ, Hamann HA, Thomas AJ, Ostroff JS. Association between patient-provider communication and lung cancer stigma. Support Care Cancer. 2016;24(5):2093-2099. PMID 26553030 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Bouazza YB, Chiairi I, El Kharbouchi O, De Backer L, Vanhoutte G, Janssens A, et al. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. Lung Cancer. 2017;113:140-151. PMID 29110842 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Fiordoliva I, Meletani T, Baleani MG, Rinaldi S, Savini A, Di Pietro Paolo M, et al. Managing hyponatremia in lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(11):711-719. PMID 29344107 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Morrison EJ, Novotny PJ, Sloan JA, Yang P, Patten CA, Ruddy KJ, et al. Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer. Clin Lung Cancer. 2017;18(5):497-503. PMID 28412094 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(5):295-301. PMID 28596092 — tags: [guidelines] — cited by: guidelines.md
• Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(7):839-849. PMID 30272503 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Hamann HA, Ver Hoeve ES, Carter-Harris L, Studts JL, Ostroff JS. Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum. J Thorac Oncol. 2018;13(8):1062-1075. PMID 29800746 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Lee YH, Liao YC, Shun SC, Lin KC, Liao WY, Chang PH, et al. Trajectories of caregiver burden and related factors in family caregivers of patients with lung cancer. Psychooncology. 2018;27(6):1493-1500. PMID 29476636 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Occhipinti S, Dunn J, O'Connell DL, Garvey G, Valery PC, Ball D, et al. Lung Cancer Stigma across the Social Network: Patient and Caregiver Perspectives. J Thorac Oncol. 2018;13(10):1443-1453. PMID 29981928 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-1453. PMID 29461916 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Shimada Y, et al. Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan. Gen Thorac Cardiovasc Surg. 2019;67(3):297-305. PMID 30328066 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Maguire R, Lewis L, Kotronoulas G, McPhelim J, Milroy R, Cataldo J. Lung cancer stigma: A concept with consequences for patients. Cancer Rep (Hoboken). 2019;2(5):e1201. PMID 32721137 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Raikhelkar J, Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019;34(3):303-306. PMID 30925516 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A, et al. Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. J Thromb Thrombolysis. 2019;47(1):121-128. PMID 30255420 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Wieland J, Hoppe BS, Rausch-Osian SM, King JC, Sierra A, Hiemenz JW, et al. Survivor and Caregiver Expectations and Preferences Regarding Lung Cancer Treatment. Int J Part Ther. 2019;6(2):42-49. PMID 31998820 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest. 2020;157(1):77-88. PMID 31374211 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Melzer AC, Golden SE, Ono SS, Datta S, Crothers K, Slatore CG. What Exactly Is Shared Decision-Making? A Qualitative Study of Shared Decision-Making in Lung Cancer Screening. J Gen Intern Med. 2020;35(2):546-553. PMID 31745852 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. PMID 31960755 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Williamson TJ, Kwon DM, Riley KE, Shen MJ, Hamann HA, Ostroff JS. Lung Cancer Stigma: Does Smoking History Matter? Ann Behav Med. 2020;54(7):535-540. PMID 31942920 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Deshwal H, Sinha A, Mehta AC. Life-Threatening Hemoptysis. Semin Respir Crit Care Med. 2021;42(1):145-159. PMID 32862418 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Friedes C, Hazell SZ, Fu W, Hu C, Voong RK, Lee B, et al. Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort Study. JCO Oncol Pract. 2021;17(8):e1094-e1109. PMID 33555936 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• McLeod H, Perlman AI, Salinas MG, Abu Dabrh AM. Caring for Caregivers-A New Integrative Care Path for Advanced Lung Cancer Patients and Their Caregivers. J Altern Complement Med. 2021;27(5):377-378. PMID 33902316 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. PMID 33687470 — tags: [guidelines] — cited by: guidelines.md
• Cochrane A, Woods S, Dunne S, Gallagher P. Unmet supportive care needs associated with quality of life for people with lung cancer: A systematic review of the evidence 2007-2020. Eur J Cancer Care (Engl). 2022;31(1):e13525. PMID 34729855 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Dai W, Feng W, Zhang Y, Wang XS, Liu Y, Pompili C, et al. Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial. J Clin Oncol. 2022;40(9):988-996. PMID 34995100 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• He Y, Sun LY, Peng KW, Luo MJ, Deng L, Tang T, et al. Sleep quality, anxiety and depression in advanced lung cancer: patients and caregivers. BMJ Support Palliat Care. 2022;12(e2):e194-e200. PMID 32253349 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• McDonnell KK, Webb LA, Adams SA, Felder TM, Davis RE. The association between lung cancer stigma and race: A descriptive correlational study. Health Expect. 2022;25(4):1539-1547. PMID 35415934 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Mudaranthakam DP, Gajewski B, Krebill H, Coulter J, Springer M, Calhoun E, et al. Barriers to Clinical Trial Participation: Comparative Study Between Rural and Urban Participants. JMIR Cancer. 2022;8(2):e33240. PMID 35451964 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• O'Gurek D, Choi HYJ. Hemoptysis: Evaluation and Management. Am Fam Physician. 2022;105(2):144-151. PMID 35166503 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Patel MI, Agrawal M, Duron Y, O'Brien D, Koontz Z. Perspectives of Low-Income and Minority Populations With Lung Cancer: A Qualitative Evaluation of Unmet Needs. JCO Oncol Pract. 2022;18(8):e1374-e1383. PMID 35696628 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Patriarcheas V, Grammoustianou M, Ptohis N, Thanou I, Kostis M, Gkiozos I, et al. Malignant Superior Vena Cava Syndrome: State of the Art. Cureus. 2022;14(1):e20924. PMID 35004083 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492-516. PMID 34932393 — tags: [guidelines, red-flags-and-safety-concerns] — cited by: guidelines.md, red-flags-and-safety-concerns.md
• El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-528. PMID 36545746 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023;13(5):393-412. PMID 37294262 — tags: [guidelines] — cited by: guidelines.md
• Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063-3071. PMID 37075273 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Otty Z, Brown A, Larkins S, Evans R, Sabesan S. Patient and carer experiences of lung cancer referral pathway in a regional health service: a qualitative study. Intern Med J. 2023;53(11):2016-2027. PMID 36710377 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov. 2023;13(5):1100-1115. PMID 36815259 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Shao H, Faris NR, Ward KD, Chen W, McHugh L, Smeltzer M, et al. Lung Cancer Patients' and Caregivers' Satisfaction With Multidisciplinary Versus Serial Care in a Community Healthcare Setting: A Prospective Comparative-Effectiveness Cohort Study. Clin Lung Cancer. 2023;24(7):e267-e274. PMID 37451932 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Wright K, Digby GC, Gyawali B, Jad R, Menard A, Moraes FY, et al. Malignant Superior Vena Cava Syndrome: A Scoping Review. J Thorac Oncol. 2023;18(10):1268-1276. PMID 37146753 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Zhu S, Yang C, Mei W, Kang L, Li T, Li J, et al. Caregiver burden for informal caregivers of patients after surgical treatment of early-stage lung cancer. J Clin Nurs. 2023;32(5-6):859-871. PMID 35869414 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Chow R, Simone CB 2nd, Rimner A. Management of malignant superior vena cava syndrome. Ann Palliat Med. 2024;13(3):620-626. PMID 38600814 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Hsu ML, Boulanger MC, Olson S, Eaton C, Prichett L, Guo M, et al. Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer. JAMA Netw Open. 2024;7(4):e246872. PMID 38630475 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Studts JL, Deffendall CM, McCubbin SL, Hamann HA, Hoover K, Brymwitt WM, et al. Examining evidence of lung cancer stigma among health-care trainees. J Natl Cancer Inst Monogr. 2024;2024(63):20-29. PMID 38836527 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Banerjee SC, Asuzu C, Mapayi B, Olunloyo B, Odiaka E, Daramola OB, et al. Feasibility, acceptability, and initial efficacy of empathic communication skills training to reduce lung cancer stigma in Nigeria: a pilot study. J Natl Cancer Inst Monogr. 2024;2024(63):30-37. PMID 38836528 — tags: [open-questions, patient-experience-and-advocacy] — cited by: OPEN-QUESTIONS.md, patient-experience-and-advocacy.md
• Yamazaki-Tan J, Harrison NJ, Marshall H, Gartner C, Runge CE, Morphett K. Interventions to Reduce Lung Cancer and COPD-Related Stigma: A Systematic Review. Ann Behav Med. 2024;58(11):729-740. PMID 39197098 — tags: [open-questions, patient-experience-and-advocacy, patient-voice] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, patient-experience-and-advocacy.md
• Takemura N, Jia S, Lin CC. Financial hardship experience in middle- and older-aged patients with advanced lung cancer. Support Care Cancer. 2024;32(6):372. PMID 38775918 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Voruganti Maddali IS, Cunningham C, McLeod L, Bahig H, Chaudhuri N, L M Chua K, et al. Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study. Lung Cancer. 2024;192:107822. PMID 38788551 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81. PMID 37909877 — tags: [guidelines] — cited by: guidelines.md
• Sridhar A, Adjei A, Montori VM, Leventakos K. Shared decision making for personalized lung cancer care. Lung Cancer. 2025;206:108614. PMID 40500650 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md